Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin.

about

Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin.

Item

http://www.wikidata.org/entity/Q42354433

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Stroke Prevention in Atrial Fi ...... nt Therapy Is No Longer a Sin.

@en

Stroke Prevention in Atrial Fi ...... nt Therapy Is No Longer a Sin.

@nl

type

Item

label

Stroke Prevention in Atrial Fi ...... nt Therapy Is No Longer a Sin.

@en

Stroke Prevention in Atrial Fi ...... nt Therapy Is No Longer a Sin.

@nl

prefLabel

Stroke Prevention in Atrial Fi ...... nt Therapy Is No Longer a Sin.

@en

Stroke Prevention in Atrial Fi ...... nt Therapy Is No Longer a Sin.

@nl

P1476

Stroke Prevention in Atrial Fi ...... nt Therapy Is No Longer a Sin.

@en

P2093

Jack Ansell

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)

Why do patients with atrial fibrillation not receive warfarin?

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.

Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.

Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis.

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.

Characterization of patients with atrial fibrillation not treated with oral anticoagulants

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

P31

scholarly article

editorial

P356

10.1161/JAHA.117.006864

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28736386

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

5586331

http://www.w3.org/2001/XMLSchema#string